Equities

PeptiDream Inc

PeptiDream Inc

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (JPY)2,816.00
  • Today's Change-23.00 / -0.81%
  • Shares traded1.48m
  • 1 Year change-43.90%
  • Beta1.0411
Data delayed at least 20 minutes, as of Nov 26 2021 06:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

  • Revenue in JPY (TTM)15.61bn
  • Net income in JPY7.11bn
  • Incorporated2006
  • Employees128.00
  • Location
    PeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
  • Phone+81 442701300
  • Websitehttps://www.peptidream.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4587:TYO since
announced
Transaction
value
FTPAnnounced02 Sep 202102 Sep 2021Announced-29.95%277.30m
Data delayed at least 20 minutes, as of Nov 26 2021 06:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
KAKEN PHARMACEUTICAL CO., LTD.75.78bn12.90bn192.49bn1.22k12.421.1512.572.54337.29337.291,981.203,657.710.4642.123.7262,368,720.007.9012.229.1014.8454.1356.3317.0219.994.59--0.027132.46-15.97-7.33-30.80-8.71-6.601.98
Sawai Group Holdings Co Ltd194.35bn10.96bn195.75bn3.00k17.880.86627.251.01249.99249.994,434.915,160.440.49351.513.1164,718,620.002.345.023.256.7837.1840.034.759.651.4446.630.220432.932.568.68-35.99-6.383.511.61
Tsumura & Co130.31bn17.21bn269.04bn3.83k15.581.1710.452.06225.00225.001,703.172,992.870.40450.75052.6534,022,190.005.205.136.386.1953.9058.0212.8511.693.00--0.176633.606.193.0511.384.074.010.00
TAKARA BIO INC.60.24bn17.28bn328.37bn1.54k19.003.8815.575.45143.52143.52500.30702.510.66161.715.4839,144,900.0019.055.7722.236.3772.2761.3328.7911.662.67--0.0022.9533.339.16149.9948.2330.0954.80
JCR Pharmaceuticals Co Ltd47.52bn14.90bn335.50bn732.0021.566.8419.927.06119.98119.98382.67378.320.64950.68993.3264,913,940.0020.368.2933.2510.6881.5169.8531.3515.611.22--0.27826.8821.4011.52157.3630.9639.7118.13
Hisamitsu Pharmaceutical Co Inc120.14bn10.56bn335.98bn2.77k30.561.2522.572.80129.10129.101,468.843,167.710.39482.643.6743,370,040.003.545.943.976.7759.3162.178.9612.635.94--0.005239.53-18.78-6.69-50.52-12.25-8.030.8601
Peptidream Inc15.61bn7.11bn369.10bn128.0051.8314.8947.8323.6554.7754.77120.22190.730.66523.9116.08121,933,600.0030.31--33.35--83.95--45.56--5.11--0.00--------------
Alfresa Holdings Corporation2.60tn20.39bn376.03bn12.05k16.610.688711.510.144896.3496.3412,268.252,323.201.9516.264.34215,587,300.001.532.643.857.256.847.330.78511.321.07--0.000327.87-3.530.2069-39.16-6.875.049.94
ROHTO PHARMACEUTICAL CO., LTD.189.30bn21.32bn397.96bn6.60k18.082.3114.022.10186.37186.371,654.741,459.500.7952.374.1828,699,510.008.986.1312.618.7558.3559.4711.306.961.64--0.079122.70-3.741.658.6512.9716.856.96
Medipal Holdings Corp3.27tn30.52bn496.63bn12.97k14.900.79339.050.1521136.35136.3514,639.422,560.321.9319.674.65251,788,700.002.402.636.517.426.627.131.241.331.06--0.04425.33-1.291.18-36.98-4.91-16.418.45
Data as of Nov 26 2021. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

22.70%Per cent of shares held by top holders
HolderShares% Held
J.O. Hambro Capital Management Ltd.as of 30 Jul 20217.18m5.52%
BlackRock Fund Advisorsas of 15 Dec 20203.78m2.91%
Nomura Asset Management Co., Ltd.as of 29 Oct 20213.54m2.72%
Invesco Advisers, Inc.as of 30 Sep 20213.05m2.35%
The Vanguard Group, Inc.as of 05 Nov 20212.30m1.77%
Baillie Gifford & Co.as of 18 Nov 20212.28m1.75%
Shiozumi Asset Management Co. Ltd.as of 30 Sep 20212.10m1.62%
Daiwa Asset Management Co. Ltd.as of 29 Oct 20211.82m1.40%
Comgest SAas of 30 Jun 20211.74m1.34%
Nikko Asset Management Co., Ltd.as of 05 Nov 20211.72m1.32%
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.